Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma
Early Phase 1
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biological: IPM001
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT05105815
- Locations
- 🇨🇳
Huashan hospital Fudan university, Shanghai, Shanghai, China
Reactogenicity and Immunogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated Vaccines
Phase 4
- Conditions
- COVID-19
- Interventions
- Drug: Vaccine, COVID19
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT05095298
- Locations
- 🇨🇳
Huashan Hospital affiliated to Fudan University, Shanghai, Jingan, China
🇨🇳Beijing Ditan Hospital Capital Medical University, Beijing, China
Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
Phase 3
Recruiting
- Conditions
- Multidrug Resistant TuberculosisRifampicin Resistant TuberculosisPre-XDR-TB
- Interventions
- Other: This is a non-intervention observational study.
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 1050
- Registration Number
- NCT05081401
- Locations
- 🇨🇳
Guiyang Public Health Treatment Center, Guiyang, Guizhou, China
🇨🇳People's Hospital of Qiandongnan, Kaili, Guizhou, China
🇨🇳The Third People's Hospital of Liupanshui, Liupanshui, Guizhou, China
A Multi-center, Prospective, Observational Study to Describe the siTuation of Blood Lipid mAnagement Among the Population With hypeRtension and/or Type 2 diabeTes in Community Health Center
- Conditions
- Lipoprotein Disorder
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 5000
- Registration Number
- NCT05081440
Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05035953
A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL
Phase 1
Active, not recruiting
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT05036577
- Locations
- 🇨🇳
Department of Hematology, Huashan Hospital, Fudan University, Shanghai, Shanghai, China
A Multicenter Phenotype-Genotype Analysis of LGMD Patients in China
- Conditions
- LGMDR1LGMDR2LGMD
- Interventions
- Diagnostic Test: ElectromyographyDiagnostic Test: IDEAL MRI
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 450
- Registration Number
- NCT04989751
- Locations
- 🇨🇳
Huashan Hospital, Shanghai, China
Early Identification and Severity Prediction of Acute Respiratory Infectious Disease
Not Applicable
Recruiting
- Conditions
- Acute Respiratory InfectionNext Generation SequencingSevere PneumoniaMultiplex PCR
- Interventions
- Diagnostic Test: mNGSDiagnostic Test: Multiplex PCR
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 440
- Registration Number
- NCT04955756
- Locations
- 🇨🇳
Department of Infectious Disease, Huashan Hospital, Shanghai, Shanghai, China
🇨🇳Central Hospital of Jingan District, Shanghai, Shanghai, China
🇨🇳Central Hospital of Minhang District, Shanghai, Shanghai, China
Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B
Recruiting
- Conditions
- Chronic Hepatitis b
- Interventions
- Drug: peginterferon alpha based regimenDrug: nucleos(t)ide
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 20000
- Registration Number
- NCT04896255
- Locations
- 🇨🇳
Huashan Hospital, Shanghai, China
Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma
Phase 2
- Conditions
- Recurrent Glioblastoma
- Interventions
- Biological: Camrelizumab plus GSC-DCVBiological: Camrelizumab plus Placebo
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04888611
- Locations
- 🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath